Bio-Technology General Corp. (NASDAQ:BTGC) of New York onWednesday said that its recombinant human growth hormonehas received marketing approval in Belgium for treatment ofshort stature. Eskatrope now has approvals in seven Europeannations. BTGC shares closed at $10.13, down 38 cents.

(c) 1997 American Health Consultants. All rights reserved.